CASE REPORT
===========

A 69-year old man was referred to our institution for a refractory sacral chordoma.

First diagnosis was performed in April 2012 through an incisional biopsy of the primitive tumor; at presentation, synchronous lung metastases were radiologically detected. The primitive mass was surgically resected *en-bloc* with distal sacrum (distal sacrectomy): pathology report confirmed the presence of a 12, 5 cm chordoma, infiltrating the surrounding soft tissues and the overlying skin with ulceration. IHC (immunohistochemistry) revealed a Brachyury, PDGFR-β and EGFR 2+ positive tumor (R pharmDx™ Dako kit) with evidence of pS6 phosphorylation in more than 70% of cells.

He received a first-line systemic therapy with a tyrosine kinase inhibitor (TKI), Imatinib 400mg, in another institution; everolimus was added to imatinib for a slight progression of disease (PD) after 4 months, reaching a disease stability (SD) for 16 months; the TKI was eventually substituted with metformin with SD.

The patient was then referred to our institution: he presented a rapid clinical deterioration of the clinical status with dyspnea on exertion; a low flow oxygen-therapy on demand was so provided. We performed a ^18^FDG-PET evaluation on July 2015 that revealed lung, bone and pelvic diffuse pathological accumulations. Afterwards, in the absence of therapeutic alternative options for a good performing patient, a challenge with an EGFR inhibitor, Erlotinib 150mg daily, was proposed.

A better tolerance to exercise with a reduction of dyspnea on exertion and no more continuous, daily demand of oxygen support was reported. However, despite a transient clinical benefit, the patient presented a new rapid clinical deterioration after 8 weeks of treatment, leading to death in September 2015.

DISCUSSION
==========

Chordoma is a rare mesenchymal tumor arising from the remnants of notochord, an embryonic midline structure common to all *Chordata*- *Phylum* members. In higher vertebrates including humans, the notochord gets ossified and contributes to the formation of vertebrae, persisting as nucleus pulposus of intervertebral discs ([@b1-tm-16-30]); however, microscopic foci can remain in the cranial and caudal portion of the spine. Chordoma is a rare bone cancer, accounting 1--4% of all bone malignancies; it arises mainly from the axial skeleton, affecting most commonly cranial and caudal bone midline sites like sacrum and skull base ([@b2-tm-16-30]).

The clinical behavior of this tumor is insidious for the unpredictable possibility of spread on bone and neural structures; moreover, the indolent and clinically silent course delays the diagnosis until advanced disease. Mostly, spine chordomas involve S4--S5 or coccygeal region protruding anteriorly into the pelvis with late onset neurological symptoms, due to neural roots compression ([@b3-tm-16-30]). Chordoma rarely presents as metastatic at first diagnosis: OS seems to be poorly affected by metastatic progression and local control appears to be correlated more to the prognosis ([@b4-tm-16-30]).

The backbone of therapy for the localized disease is surgery with wide margins without violation of tumor capsule, with a significant impact on DFS and OS ([@b5-tm-16-30]).

Concerning medical treatment, chordoma seems to be insensitive to cytotoxic chemotherapy; in a series of 33 cases published by Azzarelli ([@b6-tm-16-30]), no chemotherapeutic regimen induced a significant tumor respons though a potential response to continuous infusion ifosfamide was demonstrated in high-grade de-differentiated tumors ([@b7-tm-16-30]) as well as with combination regimen containing anthracyclines, platinum-compounds and alkylating drugs ([@b8-tm-16-30]).

This intrinsic chemo-resistance paves the way to different anti-tumor approaches, designed from biologic features and molecular characterization of chordoma. Kilgore S. showed a high expression of cyclin D1, a key regulator of cell cycle-progression in a series of 26 chordoma samples ([@b9-tm-16-30]); overexpression of CDK4, p53 and MDM2 was detected in 20--56% of sacral and skull-base chordoma, with a poor prognostic significance ([@b10-tm-16-30]). Membrane growth factor receptors (TKRs) were demonstrated to be highly expressed in chordomas: scatter factor/hepatocyte growth factor receptor (c-Met), epidermal growth factor receptor (EGFR/HER1) and different phosphorylated platelet-derived growth factor receptors (PDGFRs) seem to play a key role in tumor proliferation ([@b11-tm-16-30]); this suggests a potential role of tyrosine-kinase receptor inhibitor as therapeutics. Hence, a high-level copy number gain of 7p12 band (EGFR locus) and EGFR expression (67--81%) have been demonstrated; TKRs (PDGFR-a, c-Met, EGFR) are variously expressed in 97% of the recurrence samples analyzed ([@b12-tm-16-30]).

Furthermore, this molecular *stigmata* are potentially *druggable*. TKIs targeting angiogenesis have shown to be active against chordoma; this may probably reflect a cross-inhibition of different overlapping molecular patterns ([@b13-tm-16-30]). On this subject, Casali et. al detected an anti-tumor effect in term of tumor liquefaction, metabolic and clinical response of imatinib mesylate 800mg daily; he supposed an activity mediated by PDGFRβ-inhibition ([@b14-tm-16-30]). Similarly, a response to sunitinib 37,5 mg daily was demonstrated in a multicenter phase-II trial: 44% of chordoma patients achieved a SD concurrent to a qualitative decrease in tumor density; this pattern of response is considered to be characteristic of tumor response to VEGF-directed therapy ([@b15-tm-16-30]). Additionally, EGFR-inhibitors have shown a clinical activity, particularly in the second-line setting after imatinib failure ([@b16-tm-16-30]). Results from a phase II trial reported a modest antitumor activity of lapatinib administered at 1500mg continuously until progression or unacceptable toxicity in advanced EGFR-positive chordomas; the clinical benefit rate was 22,2% by RECIST for the intention-to-treat population ([@b17-tm-16-30]).

Siu evaluated the activity of erlotinib on a patient-derived chordoma xenograft; he showed a strong *druggable* activation of EGFR: exposure of tumor cells to erlotinib resulted in a dimensional anti-tumor response concurrent to a reduction of phosphorylation of Tyr845 residue, thus supporting a favorable clinical usage ([@b18-tm-16-30]).

Based on this molecular notion, a compassionate use of Erlotinib for relapsed-refractory chordoma can be proposed. Few recent case reports showed a clinical activity of erlotinib ([Tab 1](#t1-tm-16-30){ref-type="table"}) but its benefit has not been evaluated in a prospective trial. Indeed, a sustained response to erlotinib of a clivus-arising chordoma after imatinib failure has been described by Houessinon A. ([@b19-tm-16-30]): a 28 months continuous partial-response was reported, the longest described in literature in this setting.

CONCLUSION
==========

Our case report shows no clear clinical response to erlotinib in an imatinib-refractory sacral chordoma. Few clinical data are available to support the choice of Erlotinib in this setting, with discordant experiences reported. Therefore, a prospective trial comparing erlotinib Vs. standard therapy in different setting is warranted, considering the high rate of EGFR- positive chordomas and preclinical encouraging data. Furthermore, EGFR mutational status prognostic significance and predictive role should be clarified.

The supply of off-label erlotinib was supported by Fondazione Umberto Veronesi (FUV). We thank our patient who gently gave his consent for the publication of this case for scientific purposes.

###### 

Cases of chordoma treated with erlotinib 150mg single-agent.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sex     Localization   Previous treatment                            EGFR status (other molecular features)             EGFR status assessment                       Type of Response   Duration of response *(months)*   Reference
  ------- -------------- --------------------------------------------- -------------------------------------------------- -------------------------------------------- ------------------ --------------------------------- ----------------------------------------
  Male    Sacrum         Sur: distal sacral and coccygeal resection\   EGFR WT (PDGFR-β WT)                               EGFR 18--24 exon sequencing\                 PR                 11 OG                             Singhal N, 2009 \[[@b20-tm-16-30]\]
                         RT: 66Gy for local relapse\                                                                      FISH for EGFR and PDGFR-β                                                                         
                         Sur and imatinib 600mg\                                                                                                                                                                            
                         CYT997 (Lexibulin)                                                                                                                                                                                 

  Male    Sacrum         Sur: distal sacral and coccygeal resection\   EGFR WT\                                           IHC: 90%\                                    PR                 12                                Launay SG, 2011 \[[@b16-tm-16-30]\]
                         Post-op 60Gy RT\                              (chromosome 7 trisomy in 38% of the tumor cells)   EGFR positive tumor cells\                                                                        
                         Bone metastasis resection and RT\                                                                EGFR, KRAS, BRAF, KIT, PDGFR-α sequencing\                                                        
                         Imatinib 400mg\                                                                                  FISH for EGFR                                                                                     
                         Imatinib 600mg                                                                                                                                                                                     

  Woman   Clivus         Sur: transphenoidal tumor resection\          Not reported                                       Not reported                                 PR                 28 OG                             Houessinon A, 2015 \[[@b19-tm-16-30]\]
                         Proton therapy 68Gy\                                                                                                                                                                               
                         Imatinib 400mg\                                                                                                                                                                                    
                         Imatinib 800mg                                                                                                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sur: surgery; RT: radiotherapy; PR: partial response according to RECIST criteria; WT: wild type; OG: response ongoing at time of case report writing; post-op: post-operative; IHC: immunohistochemistry; FISH: fluorescence in-situ hybridization; EGFR: epidermal growth factor receptor; PDGF: platelet-derived growth factor.
